Reuters·1d ago
GSK, Moderna settle patent dispute over Moderna COVID, RSV shotsGSK, Moderna settle patent dispute over Moderna COVID, RSV shots
GSK's gross margin has stayed in a 68.5% to 75.4% band across the ten reported quarters, with 74.5% in 2026Q3 suggesting the specialty and vaccine mix continues to carry the portfolio, while revenue growth has moderated from 9.8% in 2024Q2 to between 1.5% and 6.7% in recent quarters.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Gross margin held near 74.5% in 2026Q3 and operating margin ranged from 2.4% to 30.3% over the period, suggesting lumpy operating expenses such as the $3.5B R&D spike in 2026Q2 continue to drive earnings volatility.
GSK's momelotinib receiving Orphan Drug Designations in the US and EU for VEXAS syndrome highlights potential for niche market expansion and regulatory advantages.
The Consumer Healthcare Capital Markets Day outlined growth ambitions and financial details, signaling a focused strategy ahead of its demerger and listing.
GSK's projected revenue of up to £55B in the bull case indicates significant growth potential, albeit dependent on innovation engine improvements.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | $1.47+5.0% vs $1.40 | $11.8B+0.4% vs $11.8B |
Q3 2026 Jul 28, 2026 | $1.36+7.1% vs $1.27 | $11.2B+1.4% vs $11.0B |
Q2 2026 Apr 29, 2026 | $1.24+6.9% vs $1.16 | $10.3B+0.7% vs $10.2B |
Q1 2026 Feb 4, 2026 | $0.68+6.3% vs $0.64 | $11.8B+3.2% vs $11.4B |
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
HP, like peers Dell Technologies, Apple and Lenovo, is caught in a global memory chip squeeze.
FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc (LSE/NYSE: GSK) that will use Alamar's NULISA™ platform in a large-scale study examining how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions.
Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines revenue rose 14%, helping offset weakness in Vaccines. HIV, Oncology and Respiratory remain key drivers of GSK's future growth. The vaccine business underperformed, with Shingrix and Arexvy missing expectations; management attributes this to China inventory reductions and broader RSV demand issues.
Benchmark GSK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for GSK plc (GSK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $50.33 | $100.84B | 17.69 | 4.11% | 12.96% | 23.31% | 3.23% | |
| $186.43 | $290.83B | 26.47 | 8.63% | 17.68% | 22.18% | 1.71% | |
| $162.55 | $308.96B | 30.86 | 5.97% | 17.82% | 24.32% | 2.47% | |
| $47.04 | $112.95B | 24.24 | 5.49% | 8.19% | 5.81% | 5.23% | |
| $29.39 | $167.51B | 41.91 | -1.65% | 6.34% | 4.58% | 5.85% | |
| $146.73 | $362.4B | 148.23 | 1.18% | 3.64% | 5.29% | 2.22% |
GSK plc (GSK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GSK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GSK plc (GSK) stock FAQ — growth, dividends, profitability & financials explained
GSK plc (GSK) reported $33.47B in revenue over the trailing twelve months. Revenue was $32.67B in fiscal year 2025. That is 292% more than the $8.34B of fiscal year 1996.
GSK plc (GSK) grew revenue by 4.1% over the trailing twelve months, compared with the twelve months before.
Yes. GSK plc (GSK) earned $4.34B in net income over the trailing twelve months (a 13.0% net margin).
Yes. GSK plc (GSK) pays a dividend that yields 3.23% at the current price, a moderate yield.
GSK plc (GSK) had a return on equity (ROE) of 23.3% over the trailing twelve months. That is well above the market's typical 10-15%.
GSK plc (GSK) generated $6.79B in free cash flow over the trailing twelve months.
